Development of an integrated genomic classifier for a novel agent in colorectal cancer: approach to individualized therapy in early development.

ABSTRACT:

Background

A plethora of agents is in early stages of development for colorectal cancer (CRC), including those that target the insulin-like growth factor I receptor (IGFIR) pathway. In the current environment of numerous cancer targets, it is imperative that patient selection strategies be developed with the intent of preliminary testing in the latter stages of phase I trials. The goal of this study was to develop and characterize predictive biomarkers for an IGFIR tyrosine kinase inhibitor, OSI-906, that could be applied in CRC-specific studies of this agent.

Methods

Twenty-seven CRC cell lines were exposed to OSI-906 and classified according to IC(50) value as sensitive (5 micromol/L). Cell lines were subjected to immunoblotting and immun

SUBMITTER: Pitts TM 

PROVIDER: S-EPMC2889230 | biostudies-literature | 2010 Jun

REPOSITORIES: biostudies-literature